L7 ANSWER 1 OF 1 ZCA COPYRIGHT 2007 ACS on STN
AN 142:280210 ZCA Full-text
TI Preparation of 2-aminobenzimidazoles as TIE-2 and Raf kinase inhibitors for the treatment of tumors
IN Hoelzemann, Guenter; Crassier, Helene; Ackermann, Karl-August; Staehle, Wolfgang; Jonczyk, Alfred; Rautenberg, Wilfried; Mitjans, Francesco; Rosell-Vives, Elisabet; Adan, Jaume; Soler, Marta
PA Merck Patent GmbH, Germany
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005019216	A1	20050303	WO 2004-EP8042	20040719 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10337942	A1	20050317	DE 2003-10337942	20030818
	AU 2004266797	A1	20050303	AU 2004-266797	20040719
	CA 2536095	A1	20050303	CA 2004-2536095	20040719
	EP 1656377	A1	20060517	EP 2004-741135	20040719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007502786	T	20070215	JP 2006-523546	20040719
	US 2007021456	A1	20070125	US 2006-568626	20060216
PRAI	DE 2003-10337942	A	20030818		
	WO 2004-EP8042	W	20040719		

GI



I



II



III

AB Title compds. I [R1 = (R4)m; R2 = (R4')p; R3 = L-Y; R4, R4' = halo, OH, CN, etc.; L = CH2, CH2CH2, O, etc.; Y = heterocycle; m, p = 0-4] and their pharmaceutically acceptable salts were prepared For example, condensation of 4-fluoronitrobenzene and isothiocyanate II, e.g., prepared from 5-hydroxy-2,1,3-benzothiadiazole in 3-steps, afforded aminobenzimidazole III. In TIE-2 tyrosine kinase receptor inhibition assays, 4-examples of compds. I exhibited IC50 values

ranging from 0.22-0.39 μM, e.g., the IC50 value of aminobenzimidazole III was 0.22 μM. Compds. I are claimed to be useful for the treatment of tumors via the inhibition of TIE-2 and Raf kinases.